Tarsa Raises $28M Series B for Coveted Oral Osteoporosis Drug
Tarsa Therapeutics Inc.'s $28 million financing will push Ostora, its once-daily oral calcitonin tablet, through a new drug application (NDA) filing and a European marketing authorization application, as well as fund other pre-commercialization activities.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST